Mounjaro/Zepbound Tracker App
Track Your Mounjaro/Zepbound Protocol
Mounjaro/Zepbound (Tirzepatide) is a gip+glp-1 dual agonist, FDA approved, used in SURMOUNT-1 with 20.9% weight loss at 72 weeks. Shotlee is the free app to track your complete Mounjaro/Zepbound protocol — doses, side effects, weight, and labs.
What Is Mounjaro/Zepbound?
Mounjaro/Zepbound (Tirzepatide) is a gip+glp-1 dual agonist, FDA approved, used in SURMOUNT-1 with 20.9% weight loss at 72 weeks. Shotlee is the free app to track your complete Mounjaro/Zepbound protocol — doses, side effects, weight, and labs.
Shotlee tracks every aspect of your Mounjaro/Zepbound protocol: injection dates, doses, sites, side effects, weight changes, and lab results. Whether you are starting or optimizing, clean data makes better decisions.
What to Track in Shotlee
Build a complete Mounjaro/Zepbound protocol record from day one.
How to Track Your Mounjaro/Zepbound Protocol
Mounjaro/Zepbound Key Facts
Protocol FAQs
Log each injection in Shotlee with the dose, date, injection site, and any side effects. Shotlee keeps a complete timeline of your Mounjaro/Zepbound protocol.
Yes. Shotlee supports tracking multiple medications and peptides simultaneously, including combination protocols.
Record every dose, injection site, timing, any side effects, and weekly weight/measurements. This data helps you and your prescriber optimize your protocol.
Yes. Shotlee is completely free for dose logging, side effect tracking, and protocol management. No hidden fees.
Track Your Mounjaro/Zepbound Protocol in Shotlee
Free dose logs, side effect tracking, weight trends, and lab results — all in one app.
📚References & sources
Latest on Tirzepatide
Eli Lilly, Novo Nordisk Address Awareness Gap for Medicare’s $50 GLP-1 Program
Learn how the new Medicare GLP-1 Bridge program works, which drugs are covered, and why major pharmaceutical companies are leading the awareness push for the $50 copay initiative.
8 min read
Eli Lilly's Retatrutide Shows Cardiovascular and Diabetic Benefits in Trials
Eli Lilly's investigational drug, retatrutide, has shown promising results in clinical trials, offering substantial weight loss and significant improvements in cardiovascular health and type 2 diabetes management.
7 min read
Truth About Mounjaro Jowls: Rosie O'Donnell's Facelift That Can't Hide Weight Loss
Rapid weight loss on GLP-1 medications often leads to skin laxity because the body loses subcutaneous fat faster than collagen and elastin can regenerate. This biological lag creates visible sagging, particularly in areas with high elasticity like the jawline and neck.
6 min read